Haemonetics (NYSE: HAE) reported Q1 EPS of $1.05, $0.32 better than the analyst estimate of $0.73. Revenue for the quarter came in at $311.3 million versus the consensus estimate of $292.69 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.